10-K: Treace Medical Concepts Reports 2025 Loss Amid Product Launches

Treace Medical Concepts, Inc. reported a net loss of $59.0 million for fiscal year 2025, despite a slight revenue increase and new product introductions in the competitive bunion correction market.

Summary

• Net loss for 2025 was $59.0 million, an increase from $55.7 million in 2024.
• Revenue increased by 1.6% to $212.7 million in 2025, up from $209.4 million in 2024.
• Gross profit increased by 0.9% to $169.8 million in 2025, but gross margin decreased from 80.4% to 79.8%.
• Sales and marketing expenses decreased by 4.6% to $140.9 million in 2025, primarily due to an $8.2 million reduction in direct-to-consumer advertising costs.
• Research and development expenses decreased by 1.5% to $20.3 million in 2025.
• General and administrative expenses increased by 12.6% to $62.7 million in 2025, driven by a $5.4 million increase in legal fees due to ongoing litigation matters.
• The company refinanced its debt in Q4 2025, entering a new 5-year senior secured loan arrangement for up to $175.0 million, borrowing $60.0 million initially. This resulted in a $2.7 million debt extinguishment loss.
• Cash and cash equivalents were $10.7 million, and marketable securities were $37.7 million as of December 31, 2025.
• Active surgeons increased by 6% to 3,337 as of December 31, 2025.
• New product launches in 2024 and full commercial release in Q3 2025 include Nanoplasty, Percuplasty, and SpeedMTP systems, which generally sell at lower average prices than the Lapiplasty System.
• The Lapiplasty System experienced lower sales due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, and lower patient demand for elective bunion surgery related to macroeconomic conditions.
• The company is involved in patent infringement lawsuits against Stryker Corporation and Zimmer Biomet Holdings, Inc./Paragon 28, Inc., and is defending against a shareholder class action complaint.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative filing. While the company shows innovation and some revenue growth, the increasing net losses, declining gross margin, and significant legal expenses, coupled with competitive pressures on its core product, indicate ongoing financial challenges despite strategic product launches.

Positives

• Revenue increased by 1.6% to $212.7 million in 2025.
• Gross profit increased by 0.9% to $169.8 million in 2025.
• Active surgeons increased by 6% to 3,337 as of December 31, 2025.
• Successful launch and full commercialization of new minimally invasive osteotomy systems (Nanoplasty, Percuplasty) and a great toe fusion system (SpeedMTP) in 2025.
• Strong clinical evidence for the Lapiplasty System, with 26 peer-reviewed publications and low recurrence rates (0.7% at 48 months, 0% at 60 months for HVA>20 degrees) reported in the ALIGN3D study.
• Next-generation Lapiplasty Lightning platform planned for commercialization in 2026, designed for faster and more accurate 3D correction.
• Expansion of the SpeedPlate Rapid Compression Implant platform to new applications and designs.
• Introduction of IntelliGuide patient-specific, pre-op planning and cut guide technology.
• Sales and marketing expenses decreased by $6.8 million (4.6%) in 2025, including an $8.2 million reduction in direct-to-consumer advertising costs.
• Successful refinancing of debt with a new 5-year senior secured loan arrangement for up to $175.0 million, providing $60.0 million initially and potential for an additional $65.0 million.
• Management's assessment of internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Net loss increased to $59.0 million in 2025 from $55.7 million in 2024.
• Gross margin decreased from 80.4% in 2024 to 79.8% in 2025, primarily due to lower margin sales to stocking distributors and increased inventory provisions.
• The flagship Lapiplasty System is experiencing lower sales due to evolving surgeon preferences for minimally invasive osteotomy procedures, increased competition, and lower patient demand for elective bunion surgery.
• New bunion systems (Nanoplasty, Percuplasty, SpeedMTP) generally sell at lower average selling prices than the Lapiplasty System, potentially impacting overall revenue and profitability.
• General and administrative expenses increased significantly by $7.0 million (12.6%) in 2025, largely due to a $5.4 million increase in legal fees from ongoing litigation.
• Interest income decreased by $2.1 million (43.1%) in 2025 due to lower cash balances and slightly lower interest rates.
• A debt extinguishment loss of $2.7 million was incurred in 2025 due to refinancing.
• The company has an accumulated deficit of $249.0 million as of December 31, 2025.
• Reliance on a limited number of suppliers for critical components, some of which are single-source.
• Macroeconomic conditions (inflation, interest rates, consumer sentiment, higher insurance costs) are negatively impacting demand for elective surgeries.
• Increased competition from larger companies bundling products and offering discounts.
• Potential for lower demand in future quarters from customers who purchased products in advance or stocking distributors building initial inventory.

Risks

• Incurring losses and potential inability to achieve or sustain profitability in the future.
• Failure to successfully market and sell existing and new products, impacting revenue and earnings.
• Operating in a very competitive business environment with larger competitors having greater resources and market share.
• Adverse effects on sales due to larger competitors utilizing established contracts and dominant market positions to induce customers to buy their bunion correction systems through bundling, rebates, and volume-based pricing.
• High dependence on the Lapiplasty System for revenue, with lower sales due to evolving surgeon preferences, competition, and macroeconomic conditions.
• Industry trends leading to increased downward pricing pressure on medical services and products.
• Macroeconomic conditions (inflation, interest rates, softening consumer sentiment, higher insurance costs, tariff policies) affecting demand for elective procedures, reducing gross margins, and increasing inventory costs.
• Uncertainty regarding the size and expected growth of the addressable market for products, which may be smaller than estimated.
• Inability to successfully demonstrate the merits of products to surgeons or address evolving preferences for minimally invasive osteotomies and MTP fusions.
• Competitors developing and commercializing similar products despite existing patents, and potential inability to enforce intellectual property rights successfully.
• Hospitals, ambulatory surgery centers, and other healthcare facilities not approving or curtailing the use of products.
• Failure to develop and retain an effective direct sales force and sales management team.
• Reliance on independent sales agencies and stocking distributors, with risks of them prioritizing competitors or terminating relationships.
• Discounted sales of products in advance to customers and stocking distributors potentially delaying reorders and decreasing revenue/gross margins in subsequent periods.
• Involvement in additional lawsuits or proceedings to protect or enforce intellectual property, which could be expensive, time-consuming, and unsuccessful, potentially leading to significant damages or prevention from selling products.
• Inadequate reimbursement levels from third-party payors for procedures using products, leading to reluctance from surgeons and patients or price reductions.
• Relationships with customers, physicians, and payors being subject to federal and state healthcare fraud and abuse laws, false claims laws, and physician payment transparency laws, with potential for substantial penalties for violations.
• Surgeons failing to safely and appropriately use products, or inability to train them effectively, leading to unsatisfactory outcomes, patient injury, negative publicity, or lawsuits.
• Problems with or changes to suppliers or manufacturers, potentially leading to inability to meet customer orders, supply disruptions, and increased costs.
• Failure to comply with federal and state quality regulations for manufacturing, leading to fines, product recalls, product liability claims, and reputational damage.
• Product liability lawsuits, warranty claims, and quality system problems harming the business.
• Misconduct or improper activities by employees and independent contractors, including noncompliance with regulatory standards.
• Infectious disease outbreaks adversely affecting business, financial condition, and results of operations.
• Loss of executive management or inability to attract and retain highly skilled personnel.
• Performance issues, service interruptions, or price increases by shipping carriers.
• Additional costs and risks from any future international expansion.
• Volatility in the market price of common stock due to various factors, including financial performance, competition, regulatory developments, and macroeconomic conditions.
• Potential for dilution if additional capital is raised through equity issuance.
• Risks associated with growth through acquisitions or investments.
• Reliance on research and reports from securities analysts, with potential for stock price decline if negative evaluations are published.
• Subject to short-selling strategies that may drive down stock price and negatively affect reputation.
• No historical or expected future dividends, limiting return on investment to stock price appreciation.
• Substantial influence of insiders over the company, potentially limiting other stockholders' ability to affect key transactions.
• Negative impact from corporate citizenship and ESG matters or reporting.
• Anti-takeover provisions discouraging changes in control or management.
• Exclusive forum provisions limiting stockholders' ability to obtain a favorable judicial forum.
• Dependence on various information technology systems, with risks of breaches, cyber-attacks, or disruptions.
• Vulnerability to interruption or loss due to natural or other disasters, power loss, strikes, and other events beyond control.
• Failure to establish and maintain an effective system of internal controls, leading to misstatements or failure to meet reporting obligations.
• Changes in tax laws or regulations or limitations on the ability to use net operating losses.
• Lengthy and expensive clinical study process with uncertain outcomes and limited long-term data.
• Misuse or off-label use of products harming reputation or leading to investigations/sanctions.
• Products causing or contributing to adverse medical events or subject to failures/malfunctions requiring FDA reporting.

Future Outlook

The company expects continued uncertainty in the macroeconomic environment, with challenges impacting demand for products and results of operations. It anticipates continued investment in business and new products for long-term revenue growth, including the commercialization of the next-generation Lapiplasty Lightning platform and the introduction of Percuplasty SuperBite Screws and SpeedTMT Rapid Compression Implant in 2026. While direct-to-patient education will continue, spending on these programs is planned to be reduced in 2026. The company believes its existing cash, cash equivalents, marketable securities, and available debt borrowings will be sufficient to fund operations for at least the next 12 months, but acknowledges that additional debt or equity financing may be required or decided upon to support further growth. Future legislative or regulatory reforms in healthcare could limit prices or reimbursement.

Management Comments

• "We have pioneered and patented the Lapiplasty 3D Bunion Correction System... addressing the root cause of the bunion, and helping patients get back to their active lifestyles."
• "We believe our Lapiplasty System was the first and remains the leading system designed to enable surgeons to consistently and reliably correct all three dimensions of the bunion deformity, stabilize the first TMT joint and allow return to weight-bearing quickly in a walking boot."
• "We believe the instrumented Nanoplasty System appeals to surgeons seeking to engage in the growing patient demand for minimally invasive osteotomy bunion surgery without the complexity and steep learning curves of current minimally invasive osteotomy systems on the market."
• "We expect the Percuplasty System to expand surgeon and patient access to the recovery and cosmetic benefits of percutaneous bunion surgery using our sophisticated instrumentation."
• "We believe that the differentiated clinical advantages of the Lapiplasty Procedure support its continued clinical adoption and have helped establish the Lapiplasty Procedure as a standard of care for bunion surgery."
• "We are investing in and executing a three-pronged strategy that focuses on rapid product innovations, a bunion-focused direct sales channel, and surgeon education programs."
• "We believe our surgeon education and training programs differentiate us from our competitors."
• "We believe that our approach to supporting surgeons leads to better clinical outcomes for patients."
• "We believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has led to, and will continue to lead to, increased pressures on the health care and medical device industry to reduce the costs of products and services."
• "We believe that our existing cash, cash equivalents, marketable securities, and available debt borrowings under our new loan facilities will allow us to continue our planned operations for at least the next 12 months."
• "We believe this serves as an enabler for obtaining the best ideas, innovating, and creating great outcomes for our customers and their patients."
• "We believe this ongoing knowledge acquisition is crucial for effective prevention, detection, mitigation, and remediation of cybersecurity incidents."

Industry Context

StockSavvy.ai notes that the medical device industry, particularly orthopaedics, is highly competitive and subject to rapid technological change and new product introductions. The shift towards minimally invasive procedures and the increasing use of ambulatory surgery centers (ASCs) are significant trends. Larger competitors leverage broad product lines and established relationships with Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) to offer bundled discounts, creating pricing pressure for specialized companies like Treace. The industry also faces increasing scrutiny from regulatory bodies regarding marketing practices and compliance with healthcare fraud and abuse laws. Macroeconomic conditions, such as inflation and higher insurance deductibles, are impacting patient demand for elective surgeries across the sector.

Comparison to Industry Standards

• Traditional 2D Osteotomy bunion surgery has a 6% to 35% patient dissatisfaction rate and 3.6% to 78% recurrence rates, while traditional Lapidus Fusion has a 7% to 13% dissatisfaction rate and 38% recurrence rate.
• The Lapiplasty Procedure demonstrated a 0.7% recurrence rate (HVA>20 degrees) at 48 months and 0% at 60 months (n=84) in the ALIGN3D study, significantly lower than traditional methods.
• Early return to weight-bearing in a walking boot for Lapiplasty patients averaged 7.7 days (ALIGN3D interim analysis) and 7.9 days (Mini3D study), which is faster than the 6-10 weeks non-weight bearing reported for conventional Lapidus Fusion.
• The company's employee engagement survey in 2024 showed 79% employee engagement, which compares favorably with average engagement of 73% of the medical device and biotechnology companies in the benchmark compiled by the independent third-party consulting firm.
• Stryker Corporation is identified as the leader in the orthopaedic foot and ankle market with significant market share, and other large competitors include Arthrex, Inc., Paragon 28, Inc., Zimmer Biomet Holdings, Inc., DePuy Synthes Products, Inc. (Johnson & Johnson subsidiary), CrossRoads Extremity Systems, Enovis Corporation, CONMED Corporation, Medartis Holdings AG, Nextremity Solutions, Inc., Medline Industries, Inc., and Henry Schein, Inc. These larger competitors have greater financial resources and broader product lines, allowing them to bundle products and offer rebates, which is a competitive challenge for Treace.

Corporate Governance

Legal Proceedings

• Shareholder Class Action Complaint: Filed April 11, 2025, in the U.S. District Court for the Middle District of Florida (McCluney v. Treace Medical Concepts, Inc. et al. Case No. 3:25-cv-00390-WWB-PDB) against the company and certain officers. Alleges violations of federal securities laws by making false or misleading statements and failing to disclose material adverse facts about competition and product demand between May 8, 2023, and May 7, 2024. Plaintiffs seek unspecified monetary damages, costs, and attorneys' fees. The company disputes allegations and intends to defend vigorously. Outcome is uncertain.
• Patent Infringement Lawsuit (vs. Stryker): Filed October 14, 2024, against Stryker Corporation and Wright Medical Technology, Inc. in the U.S. District Court for the District of New Jersey, alleging infringement of 9 patents related to Lapiplasty 3D Bunion Correction technologies and unfair competition. Seeks injunctive relief and damages. Stryker's motion to dismiss unfair competition claims was granted without prejudice on October 2, 2025. The company filed an amended complaint on October 24, 2025, and Stryker filed another motion to dismiss on December 5, 2025. Discovery is ongoing.
• Patent Infringement Lawsuit (by Stryker): Filed May 23, 2025, by Stryker European Operations Holdings LLC and Howmedica Osteonics Corp. against the company for patent infringement by its hammertoe product. Plaintiffs seek findings of infringement, equitable relief, unspecified monetary damages, enhanced damages for willful infringement, interest, costs, and attorneys' fees. The company disputes allegations and moved to dismiss on August 4, 2025, which was denied. Outcome is uncertain.
• Patent Infringement Lawsuit (vs. Zimmer Biomet/Paragon 28): Filed May 12, 2025, against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. in the U.S. District Court for the District of Delaware, alleging infringement of 4 patents related to Lapiplasty 3D Bunion Correction technologies. An amended complaint was filed on August 5, 2025, adding an additional patent. Defendants moved to dismiss certain patent claims, willful infringement claims, and all claims against Zimmer Biomet Holdings, Inc. on December 19, 2025. Paragon 28 filed petitions for inter partes review and post-grant review in December 2025 and January 2026, challenging the validity of four of the five patents.
• Trade Secret/Copyright Infringement Lawsuit (by Paragon 28/Disior Oy): Filed August 29, 2025, by Paragon 28, Inc. and Disior Oy against the company and RPM-3D in the U.S. District Court for the District of Delaware. Alleges RPM-3D improperly acquired, used, and disclosed confidential and trade secret technology from Disior's software to develop software acquired by the company. An amended complaint on December 18, 2025, added patent and copyright infringement claims. The deadline for response is February 17, 2026. Outcome is uncertain.

Related Party Transactions

• Royalty agreements with surgeon consultants: The company has royalty agreements with certain members of its Surgeon Advisory Board and other surgeon consultants, providing royalties based on individual contribution (0.2% to 3.0% of net sales for the particular product). These agreements prohibit payment of royalties on products sold to entities/individuals with whom the surgeon advisor is affiliated. Royalty expense was $6.4 million in 2025 and $6.8 million in 2024.
• Product development and fee-for-service agreements with Surgeon Advisory Board and other surgeon consultants.

Stakeholder Impact

• Shareholders: Increased net loss and declining gross margin could negatively impact stock price. Dilution risk if future capital raises involve equity. Shareholder class action lawsuit adds uncertainty.
• Employees: Turnover in sales force due to optimization efforts. Continued investment in talent acquisition, management, and development. Equity programs (stock options, RSUs) for approximately 80% of employees. High employee engagement (79%) compared to industry average.
• Customers (Surgeons, Hospitals, ASCs): New product offerings (Nanoplasty, Percuplasty, SpeedMTP) and next-generation Lapiplasty Lightning aim to meet evolving preferences and improve surgical outcomes. Extensive training programs provided. However, competitive bundling practices and pricing pressures from larger competitors could limit access to customers.
• Patients: Benefits from new product innovations and clinical evidence supporting Lapiplasty's effectiveness and low recurrence rates. Direct-to-patient outreach programs aim to increase awareness. Risks of product liability claims or adverse events.
• Suppliers: Reliance on a limited number of suppliers, some single-source, poses supply chain risk. Macroeconomic conditions could strain suppliers.
• Creditors: New $175.0 million senior secured loan arrangement with SLR Investment Corp. and Gemino Healthcare Finance, LLC. Existing debt repaid. Subject to financial covenants (minimum liquidity, minimum revenue if liquidity threshold not met).

Next Steps

• Commercialize the next-generation Lapiplasty Lightning platform in 2026.
• Introduce Percuplasty SuperBite Screws in 2026.
• Begin limited market release of the SpeedTMT Rapid Compression Implant in early 2026.
• Continue direct-to-patient education program, but with reduced spending in 2026.
• Continue to invest capital in expanding product offerings, sales force, surgeon education, and R&D efforts.
• Continue to pursue development and potential commercialization of new products for concomitant pathologies.
• Continue three prospective, multicenter, post-market clinical studies (ALIGN3D, MTA3D, SPRINT).
• Defend against ongoing patent infringement lawsuits and a shareholder class action complaint.
• File the 2026 Proxy Statement within 120 days after December 31, 2025.

Key Dates

Recommendation

Treace Medical Concepts is in a challenging transition, balancing innovation with significant financial losses and intense competition. While new product launches and strong clinical data for Lapiplasty are positive, the declining gross margin, increasing legal expenses, and macroeconomic headwinds impacting elective procedures create substantial uncertainty. The ongoing patent litigation and shareholder lawsuit add further risk. A "hold" recommendation is appropriate as the company navigates these challenges; investors should monitor the adoption rate of new products, the resolution of legal disputes, and progress towards profitability before making further investment decisions.

Keywords

Bunion correction, Lapiplasty, Medical devices, Foot and ankle surgery, Orthopaedics, Minimally invasive surgery, SEC filing, Financial results, Healthcare technology, Surgical implants, Intellectual property litigation, Corporate governance, Risk factors, Financial performance, Product development